- Home
- SRZN vs MGNX Comparison
SRZN vs MGNX Comparison
Compare SRZN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- MGNX
- Stock Information
- Founded
- SRZN 2015
- MGNX 2000
- Country
- SRZN United States
- MGNX United States
- Employees
- SRZN N/A
- MGNX N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- MGNX Health Care
- Exchange
- SRZN Nasdaq
- MGNX Nasdaq
- Market Cap
- SRZN 97.3M
- MGNX 99.7M
- IPO Year
- SRZN N/A
- MGNX 2013
- Fundamental
- Price
- SRZN N/A
- MGNX $1.78
- Analyst Decision
- SRZN Strong Buy
- MGNX Hold
- Analyst Count
- SRZN 2
- MGNX 6
- Target Price
- SRZN $38.50
- MGNX $3.20
- AVG Volume (30 Days)
- SRZN 29.4K
- MGNX 614.2K
- Earning Date
- SRZN 11-05-2025
- MGNX 11-04-2025
- Dividend Yield
- SRZN N/A
- MGNX N/A
- EPS Growth
- SRZN N/A
- MGNX N/A
- EPS
- SRZN N/A
- MGNX N/A
- Revenue
- SRZN $12,621,000.00
- MGNX $165,495,000.00
- Revenue This Year
- SRZN N/A
- MGNX N/A
- Revenue Next Year
- SRZN N/A
- MGNX N/A
- P/E Ratio
- SRZN N/A
- MGNX N/A
- Revenue Growth
- SRZN N/A
- MGNX 303.47
- 52 Week Low
- SRZN $5.90
- MGNX $0.99
- 52 Week High
- SRZN $18.17
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- SRZN 71.33
- MGNX 51.87
- Support Level
- SRZN $13.28
- MGNX $1.69
- Resistance Level
- SRZN $15.06
- MGNX $1.83
- Average True Range (ATR)
- SRZN 0.73
- MGNX 0.10
- MACD
- SRZN 0.15
- MGNX 0.00
- Stochastic Oscillator
- SRZN 67.62
- MGNX 56.00
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.